Fortive Corporation (FTV)
Industrial / Instrumentación y Dispositivos Médicos
Fortive is a portfolio of niche brands in industrial instrumentation (Fluke) and regulated medical devices (Advanced Sterilization Products), restructured after the Ralliant spin-off in 2025, with core growth accelerating to 6.7% and operating margin expanding via the Fortive Business System; however, GAAP operating profit —depressed by intangible amortization from a history of acquisitions— trades at a multiple (~28x EV/EBIT) far above what the disciplined band of the industrial archetype (12-18x) justifies, so Overvalued.
- Price
- $59.61
- Intrinsic value (5y, base)
- $56
- Total annual return (5y)
- -0.8%
- Status (nominal)
- Overvalued
- Margin of safety
- No margin
The essentials
- Two segments of a different nature — general industrial instrumentation and FDA-regulated medical devices — valued separately (sum of the parts).
- Core growth accelerating to 6.7% in Q2 2026, with operating margin expansion of 330 basis points year over year.
- Aggressive buybacks (~11% of shares over four quarters) financed in part with short-term debt, on top of GAAP operating profit depressed by intangible amortization.
Intrinsic value — two valuation methods
Total return at 5 years: -0.8%/year = -1.2% appreciation + 0.4% dividend. The target price ($56) is ex-dividend; the $1 in dividends collected over 5 years are added separately.
The methods disagree: one places the value today above the price ($60) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $60 trades ~29.4% above its value discounted to today (~$46); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$29.
Thesis
The business
Fortive is a portfolio of niche brands restructured after the Ralliant spin-off in 2025, with two segments of a different nature: general industrial instrumentation (Intelligent Operating Solutions) and FDA-regulated medical devices (Advanced Healthcare Solutions). Core growth accelerates to 6.7% in the second quarter of 2026 and operating margin expands 330 basis points year over year, driven by the Fortive Business System, although the simultaneous transition of CEO, CFO, and Chief People Officer introduces short-term execution risk.
The valuation
Each segment is valued separately —sum of the parts— with its own EV/EBIT multiple within its archetype's band: Intelligent Operating Solutions at 15x (industrial band 12-18x) and Advanced Healthcare Solutions at 18x (med-tech band 16-22x). GAAP operating profit is depressed by roughly US$370 million a year of acquisition-related intangible amortization, which makes the current EV/EBIT multiple (~28x) look far above the disciplined terminal (~15.5x blend). The 5-year value is $56 versus the current price, a total return of -1% annually.
The margin of safety
No margin of safety: the price already discounts a demanding scenario. No compelling missing-buyer or motivated-seller discount source was identified beyond the light analyst coverage following the spin-off and the leadership transition; the current price may also reasonably reflect the market valuing adjusted non-GAAP EPS over the disciplined GAAP EBIT of this method, so Overvalued.
What to watch
The main disconfirmer is whether Advanced Healthcare Solutions reverses the volume decline from healthcare policy: if the segment's margin stalls below 12%, the base case loses support. The second is whether the pace of buybacks —financed in part with commercial paper and short-term debt— proves sustainable with the free cash flow generated, or slows sooner than modeled.
Educational / informational. Does not constitute investment advice.